BESPOKE: Highlighting the Disease-Free Survival by ctDNA Status

Opinion
Video

Panelists discuss how BESPOKE trial results demonstrate significantly improved disease-free survival rates in patients with negative circulating tumor DNA (ctDNA) status compared with those with detectable ctDNA, underscoring its potential as a powerful prognostic biomarker.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
6 experts are featured in this series.
6 experts are featured in this series.
Related Content